Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,556 matching trials from the live ClinicalTrials.gov search.
Conditions
Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia Type 6
Interventions
Deep Brain Stimulation (DBS)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
San Francisco, California
Recruiting Phase 2 Interventional

CBIT+TMS R33 Phase

NCT06678737
Conditions
Tics, Tourette Syndrome
Interventions
CBIT +cTBS, CBIT +sham cTBS
Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Temporarily Not Available No phase listed Expanded access

Intermediate Expanded Access Protocol CNMAu8.EAP04

NCT06408727
Conditions
ALS, Amyotrophic Lateral Sclerosis, PALS
Interventions
CNM-Au8
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years and older
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Chicago, Illinois • Iowa City, Iowa + 4 more
Conditions
Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia
Interventions
rituximab
Drug
Lead sponsor
National Pediatric Neuroinflammation Organization, Inc.
Other
Eligibility
6 Months to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Illinois
Conditions
Alzheimer Disease, Gut Biome
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years to 90 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Fish Oil Brain Delivery Study

NCT02541929
Conditions
Brain Health
Interventions
Docosahexaenoic acid
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Conditions
Parkinson Disease
Interventions
Prebiotic Bar
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Friedreich Ataxia
Interventions
Methylprednisolone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimers Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Conditions
Neurofibromatosis Type 1
Interventions
CogmedRM, Mobymax
Other
Lead sponsor
Kristina Hardy
Other
Eligibility
8 Years to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Essential Tremor, Parkinson's Disease, Dystonia
Interventions
Multifunctional Apparatus for Voltammetry, Electrophysiology, and Neuromodulation (MAVEN)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

MIBG in Aging and Neurologic Disorders

NCT05514106
Conditions
Lewy Body Disease, Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alzheimer's Disease
Interventions
Creatine Monohydrate
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Alzheimer's Disease
Interventions
[123I]MNI-672 SPECT
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

Human Brain Antioxidants During Oxidative Stress

NCT01713816
Conditions
Oxidative Stress, Alzheimer's Disease, Aging
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Neurodegenerative Diseases, sca3, MSA - Multiple System Atrophy, Ataxia, Synucleinopathies
Interventions
18F-PBR06, 18F-PBR06
Drug · Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Alzheimer Disease
Interventions
SHUTi OASIS, Patient Education
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Conditions
Epilepsy, Tuberous Sclerosis Complex
Interventions
Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Conditions
Progressive Supranuclear Palsy
Interventions
alpha-lipoic acid and L-acetyl carnitine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
SBT101 Treatment
Genetic
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Autonomic Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Interventions
Miransertib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more